Skip to main content

Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for patients with metastatic colorectal cancer in the VA's National Precision Oncology Program (NPOP)

Publication ,  Conference
Djotsa, AN; Winski, D; Nguyen, TH-A; Ahmed, S; Strickler, JH; Becker, DJ; Vashistha, V; Kelley, MJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2023

Volume

41

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Djotsa, A. N., Winski, D., Nguyen, T.-A., Ahmed, S., Strickler, J. H., Becker, D. J., … Kelley, M. J. (2023). Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for patients with metastatic colorectal cancer in the VA's National Precision Oncology Program (NPOP). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Djotsa, Alice Nono, David Winski, Theresa Hoang-Anh Nguyen, Sara Ahmed, John H. Strickler, Daniel Jacob Becker, Vishal Vashistha, and Michael J. Kelley. “Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for patients with metastatic colorectal cancer in the VA's National Precision Oncology Program (NPOP).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Djotsa AN, Winski D, Nguyen TH-A, Ahmed S, Strickler JH, Becker DJ, Vashistha V, Kelley MJ. Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for patients with metastatic colorectal cancer in the VA's National Precision Oncology Program (NPOP). JOURNAL OF CLINICAL ONCOLOGY. 2023.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2023

Volume

41

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences